Pharmacotherapy for Obesity
Patient Selection and Treatment
- The American Heart Association recommends pharmacotherapy for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, using GLP-1 receptor agonists as first-line agents due to their superior weight loss efficacy and cardiovascular benefits 1
- Patients must meet specific BMI thresholds: BMI ≥30 kg/m² regardless of comorbidities 2, 3, 4
- For Asian populations, lower thresholds apply: BMI >27 kg/m² or >25 kg/m² with complications 6, 7
First-Line Pharmacotherapy Options
- GLP-1 receptor agonists, such as semaglutide 2.4 mg weekly, achieve 6.8% placebo-subtracted weight loss and demonstrate cardiovascular event reduction in patients with preexisting cardiovascular disease 1
- Liraglutide 3.0 mg daily produces approximately 5.4% placebo-subtracted weight loss at 12+ months, although the exact citation for this is not provided, it is mentioned in the context of 1
Critical Implementation Requirements
- Pharmacotherapy must be used in conjunction with lifestyle modification, including diet, exercise, and behavioral therapy, as combined therapy produces superior results compared to either approach alone 2, 6, 7
- Treatment should be continued long-term to maintain weight loss and health benefits, as weight regain occurs when therapy is stopped 2, 6, 7
Monitoring and Response Assessment
- Assess patients monthly for the first 3 months, then at least every 3 months, and discontinue medication if <5% weight loss after 12 weeks on maximally tolerated dose 5, 6, 7
- Consider alternative medication or intensify treatment with additional approaches if weight loss goals are not met 1
Special Population Considerations
- For patients with type 2 diabetes, prioritize GLP-1 receptor agonists or dual GIP/GLP-1 agonists for combined glycemic control and weight loss, as these agents provide weight-independent cardiovascular and metabolic benefits 1
- For patients with cardiovascular disease, avoid sympathomimetic agents and use liraglutide or orlistat as safer alternatives, as semaglutide 2.4 mg demonstrated cardiovascular event reduction in this population 1, 5